**Supplementary Table 3.** Baseline characteristics by PR quartiles

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **Total Population** | **PR** **quartiles (ms)** | | | | **P-trend** |
| **N=2,759** | **Q1 (<154)**  **N=722** | **Q2 (154-168)**  **N=701** | **Q3 (170-188)**  **N=681** | **Q4 (>188)**  **N=639** |
| Age (years) | 58 ± 11 | 54 ± 12 | 57 ± 11 | 59 ± 10 | 61 ± 10 | <0.001 |
| Male | 1,505 (55%) | 322 (45%) | 380 (54%) | 387 (57%) | 403 (63%) | <0.001 |
| Race/ethnicity |  |  |  |  |  | 0.01 |
| White | 1,281 (46%) | 369 (51%) | 340 (49%) | 302 (44%) | 261 (41%) |  |
| Black | 1,206 (44%) | 258 (36%) | 295 (42%) | 316 (46%) | 331 (52%) |  |
| Other | 272 (10%) | 95 (13%) | 66 (9%) | 63 (9%) | 47 (7%) |  |
| Body mass index (kg/m2) | 31.9 ± 7.8 | 30.5 ± 7.8 | 31.1 ± 7.4 | 32.5 ± 8.1 | 33.5 ± 7.7 | <0.001 |
| Diabetes | 1,256 (46%) | 298 (41%) | 300 (43%) | 334 (49%) | 316 (50%) | <0.001 |
| Systolic blood pressure | 128 ± 22 | 125 ± 22 | 128 ± 22 | 129 ± 21 | 129 ± 21 | <0.001 |
| Coronary artery disease | 511 (19%) | 98 (14%) | 109 (16%) | 139 (20%) | 159 (25%) | <0.001 |
| Heart failure | 170 (6%) | 41 (6%) | 27 (4%) | 41 (6%) | 56 (9%) | <0.01 |
| Stroke | 247 (9%) | 42 (6%) | 69 (10%) | 70 (10%) | 65 (10%) | <0.01 |
| eGFR (CKD-EPI, ml/min/1.73 m²) | 45 ± 15 | 47 ± 16 | 46 ± 15 | 45 ± 15 | 44 ± 14 | <0.001 |
| 24-hour urine protein (g/24h) | 0.17  [0.07-0.82] | 0.16  [0.07-0.96] | 0.15  [0.07-0.76] | 0.20  [0.08-0.84] | 0.18  [0.07-0.76] | 0.60 |
| Hematocrit (%) | 37.9 ± 5.0 | 37.8 ± 4.9 | 38.3 ± 5.2 | 37.9 ± 4.9 | 37.7 ± 4.9 | 0.43 |
| Serum albumin (g/dL) | 3.96 ± 0.46 | 3.91 ± 0.49 | 4.00 ± 0.46 | 3.97 ± 0.45 | 3.99 ± 0.43 | <0.01 |
| Serum potassium (mEq/L) | 4.35 ± 0.53 | 4.40 ± 0.55 | 4.36 ± 0.50 | 4.34 ± 0.52 | 4.27 ± 0.54 | <0.001 |
| Serum calcium (mg/dL) | 9.20 ± 0.50 | 9.17 ± 0.53 | 9.21 ± 0.50 | 9.20 ± 0.50 | 9.23 ± 0.49 | 0.05 |
| ACEI or ARB use | 1,867 (68%) | 449 (63%) | 472 (68%) | 481 (71%) | 455 (72%) | <0.001 |
| Beta blocker use | 1,260 (46%) | 251 (35%) | 301 (43%) | 325 (48%) | 373 (59%) | <0.001 |
| Calcium channel blocker use | 1,095 (40%) | 210 (29%) | 254 (37%) | 299 (44%) | 325 (51%) | <0.001 |
| Potassium sparing diuretic use | 261 (10%) | 53 (7%) | 63 (9%) | 63 (9%) | 79 (12%) | <0.01 |
| Loop diuretic use | 943 (34%) | 210 (29%) | 225 (32%) | 239 (35%) | 263 (41%) | <0.001 |
| Thiazide diuretic use | 790 (29%) | 170 (24%) | 208 (30%) | 183 (27%) | 222 (35%) | <0.001 |
| Statin use | 1,483 (54%) | 332 (46%) | 375 (54%) | 398 (59%) | 370 (58%) | <0.001 |
| Warfarin use | 71 (2.6%) | 19 (2.6%) | 13 (1.9%) | 18 (2.6%) | 19 (3.0%) | 0.52 |

Note: Continuous variables presented as mean ± standard deviation if normally distributed or median (25th-75th percentile) if non-normally distributed; categorical variables presented as count (%).

Baseline characteristics, according to quartiles of PR, were compared with tests for trend based on linear regression, chi-square trend test, and the Cuzick nonparametric trend test.

Abbreviations. eGFR: estimated glomerular filtration rate, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker.